Difference between revisions of "Cemiplimab (Libtayo)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Immunotherapy" to "Category:Immunotherapeutic") |
(added package insert, links) |
||
| Line 1: | Line 1: | ||
| − | == | + | ==General information== |
| − | + | Class/mechanism: PD-1 antibody. Cemiplimab is a recombinant human monoclonal antibody which binds to the PD-1 receptor on T-cells and blocks its interaction with PD-L1 and PD-L2, which immune system inhibition and facilitates anti-tumor immune response.<ref name="insert">[https://www.regeneron.com/sites/default/files/Libtayo_FPI.pdf Cemiplimab (Libtayo) package insert]</ref><ref>[[Media:Cemiplimab.pdf | Cemiplimab (Libtayo) package insert (locally hosted backup)]]</ref><ref>[https://www.libtayohcp.com/ Libtayo manufacturer's website]</ref> | |
| + | <br>Route: IV | ||
| + | <br>Extravasation: no information | ||
| + | |||
| + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name=insert></ref> | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Cutaneous squamous cell carcinoma]] | *[[Cutaneous squamous cell carcinoma]] | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[https://www.regeneron.com/sites/default/files/Libtayo_FPI.pdf Cemiplimab (Libtayo) package insert]<ref name="insert" /> | ||
| + | *[http://chemocare.com/chemotherapy/drug-info/cemiplimab-rwlc.aspx Cemiplimab (Libtayo) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cemiplimab-rwlc.aspx Cemiplimab (Libtayo) patient drug information (Chemocare)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *9/28/2018: | + | *9/28/2018: [https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-advanced-form-second-most-common-skin-cancer-0 FDA approved] "for patients with [[Cutaneous squamous cell carcinoma|metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC]] who are not candidates for curative surgery or curative radiation." |
| + | |||
==Also known as== | ==Also known as== | ||
*'''Code name:''' REGN2810 | *'''Code name:''' REGN2810 | ||
*'''Generic name:''' cemiplimab-rwlc | *'''Generic name:''' cemiplimab-rwlc | ||
*'''Brand name:''' Libtayo | *'''Brand name:''' Libtayo | ||
| + | |||
| + | ==References== | ||
| + | <references /> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 22:22, 12 May 2019
General information
Class/mechanism: PD-1 antibody. Cemiplimab is a recombinant human monoclonal antibody which binds to the PD-1 receptor on T-cells and blocks its interaction with PD-L1 and PD-L2, which immune system inhibition and facilitates anti-tumor immune response.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 9/28/2018: FDA approved "for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation."
Also known as
- Code name: REGN2810
- Generic name: cemiplimab-rwlc
- Brand name: Libtayo